



FOR SINGAPORE MEDIA ONLY

10 February 2025
Singapore

Statement by Raakhi Sippy (General Manager, GSK Singapore), on behalf of GSK Singapore, on the news of the Singapore Ministry of Health (MOH) extending subsidies and MediSave usage for the shingles vaccine for eligible Singaporeans and Permanent Residents

“We are delighted for the people of Singapore on the major step forward the Ministry of Health (MOH) has taken to protect adults aged 60 years or older, as well as immunocompromised adults aged 18-59 years, from shingles and related complications.”

“The decision of the MOH to extend subsidies and MediSave usage for the shingles vaccine for eligible Singaporeans and Permanent Residents at public healthcare institutions and General Practitioner (GP) clinics under the Community Health Assist Scheme (CHAS) ensures that people in Singapore have access to the vaccine, where and when they need it, and plays a crucial role in safeguarding the health, wellbeing, and prosperity of the rapidly ageing society.”

“Singapore is leading the way in Asia-Pacific to offer a comprehensive shingles vaccination programme for adults aged 60 years or older as well as immunocompromised adults aged 18-59 years. This initiative marks a significant milestone in public health, setting what could be a new standard for shingles preventive care across the region.”

“We appreciate the trust placed in GSK to supply for the implementation of Singapore’s shingles vaccination programme as part of the National Adult Immunisation Schedule (NAIS) and we will continue to work together with the MOH and all related parties to deliver the vaccine to those who need it.”

- End of Statement -

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at <https://www.gsk.com>

For media queries, please contact:

Rifdi Jaffar
TEAM LEWIS (on behalf of GSK Singapore)
GSK@teamlewis.com

Rommel Abuda
GSK
rommel.j.abuda@gsk.com

